Journal of Medicinal Chemistry p. 1086 - 1097 (2018)
Update date:2022-08-04
Topics:
Piotrowski, David W.
Futatsugi, Kentaro
Casimiro-Garcia, Agustin
Wei, Liuqing
Sammons, Matthew F.
Herr, Michael
Jiao, Wenhua
Lavergne, Sophie Y.
Coffey, Steven B.
Wright, Stephen W.
Song, Kun
Loria, Paula M.
Banker, Mary Ellen
Petersen, Donna N.
Bauman, Jonathan
A novel series of morpholine-based nonsteroidal mineralocorticoid receptor antagonists is reported. Starting from a pyrrolidine HTS hit 9 that possessed modest potency but excellect selectivity versus related nuclear hormone receptors, a series of libraries led to identification of morpholine lead 10. After further optimization, cis disubstituted morpholine 22 was discovered, which showed a 45-fold boost in binding affinity and corresponding functional potency compared to 13. While 22 had high clearance in rat, it provided sufficient exposure at high doses to favorably assess in vivo efficacy (increased urinary Na+/K+ ratio) and safety. In contrast to rat, the dog and human MetID and PK profiles of 22 were adequate, suggesting that it could be suitable as a potential clinical asset.
View Morewebsite:http://www.weichichem.com
Contact:+8613912949432
Address:Fine Chemical Industrial Base,Wujiang town,He County,Anhui China.
Contact:+86+21-58956006 15800617331
Address:402 Room, 150# Cailun Road, Zhangjiang high tech park, Shanghai
Baoding City Light Industry And Textiles Imp.& Exp. Corp. Chemical Department.
Contact:86-312-3262436
Address:NO.658 CHAOYANG SOUTH STREET,BAODING CITY HEBEI CHINA
Contact:0086-29-88315623
Address:S711, Innovation Bldg No.25 Gaoxin 1st Rd, Xian P.R of China 710075
Jinhua City Mingzhu Pharmaceutical Co.,Ltd.
Contact:15857995878 0579-82207761
Address:No.169 Shenze Road, New Area,Jinpan Development Zone, Jinhua
Doi:10.1016/0022-328X(91)86057-W
(1991)Doi:10.1039/c2ob06942c
(2012)Doi:10.1016/0022-328X(91)80062-O
(1991)Doi:10.1016/j.poly.2012.02.024
(2012)Doi:10.1002/anie.201109130
(2012)Doi:10.1007/s10600-012-0212-6
(2012)